Stock Market Reviews

VKTX (Viking Therapeutics, Inc.) News

Get the latest news, insights, and market updates on VKTX (Viking Therapeutics, Inc.). Explore the news page 2 on MyTopStock.com for investor discussions, analysis, and real-time stock performance coverage.

• Viking Therapeutics, Inc. (VKTX): A Bull Case Theory
  We came across a bullish thesis on Viking Therapeutics, Inc. on Alpha Talon Investment Research’s Substack by AT Investment Research. In this article, we will summarize the bulls’ thesis on VKTX. Viking Therapeutics, Inc.’s share was trading at $36.15 as of December 15th. Viking Therapeutics is a clinical-stage biotechnology company focused on metabolic and endocrine disorders, with its […]
  Dec 18, 2025 - $VKTX
• Viking Therapeutics (VKTX): Rethinking Valuation After a Sharp Pullback and Strong Multi‑Year Run
  Viking Therapeutics (VKTX) has been on a wild ride this year, with shares sliding over the past month even after a massive run in the past 3 years. So what is the market rethinking here? See our latest analysis for Viking Therapeutics. At around $35.72 today, Viking’s recent pullback, including a weak 1 month share price return, looks more like a breather after a powerful 3 year total shareholder return that still signals strong long term optimism. If this kind of volatility has your...
  Dec 17, 2025 - $VKTX
• Viking Therapeutics (VKTX) Deemed ‘Extremely Attractive’ and Undervalued by Canaccord, Cited as Leader in Obesity Clinical Development
  Viking Therapeutics Inc. (NASDAQ:VKTX) is one of the stocks that will double in 2026. Earlier on November 12, Canaccord raised the firm’s price target on Viking Therapeutics to $107 from $106 with a Buy rating on the shares. Canaccord considers Viking Therapeutics’ shares to be significantly undervalued, especially when factoring in the more advanced stage […]
  Dec 16, 2025 - $VKTX
• 2 Monster Stocks in the Making to Buy and Hold
  The next 12 months will tell us more about their prospects.
  Dec 16, 2025 - $VKTX
• 1 Bold Prediction for Viking Therapeutics in 2026
  Viking's pipeline may release its value next year, and larger companies are likely to consider acquiring it.
  Dec 16, 2025 - $VKTX
• Viking Therapeutics, Inc. (VKTX) Registers a Bigger Fall Than the Market: Important Facts to Note
  Viking Therapeutics, Inc. (VKTX) closed at $36.15 in the latest trading session, marking a -2.51% move from the prior day.
  Dec 15, 2025 - $VKTX
• This is why Viking Therapeutics, Inc. (VKTX) is a Strong Buy on Wall Street
  Viking Therapeutics, Inc. (NASDAQ:VKTX) is one of the best biotech stocks to buy according to Wall Street analysts. On November 20, H.C. Wainwright reaffirmed its Buy rating and $102 price target on Viking Therapeutics, Inc. (NASDAQ:VKTX) after the company finished enrollment ahead of schedule in its Phase 3 VANQUISH-1 obesity study, bringing in 4,650 adults […]
  Dec 11, 2025 - $VKTX
• Unusual Bullish Options Activity Could Be A Game Changer For Viking Therapeutics (VKTX)
  In recent days, options scanners identified unusually large and mostly bullish options trades in Viking Therapeutics, pointing to elevated interest from major investors. This burst of complex options activity suggests that some large market participants may be positioning for meaningful company-specific developments beyond ordinary trading patterns. Against this backdrop of heightened bullish options positioning, we’ll explore how these moves by large investors could shape Viking...
  Dec 11, 2025 - $VKTX
• 3 Underrated Growth Stocks That Look Like Great Buys Heading Into 2026
  These stocks are underperforming the market this year, but that trend may not last for long.
  Dec 11, 2025 - $VKTX
• Eli Lilly's Experimental Obesity Drug Cut Weight By 23.7%
  Eli Lily rose above a key level after saying its experimental obesity treatment delivered 23.7% weight loss in a late-stage trial.
  Dec 11, 2025 - $VKTX